Logo

Benitec Issued Dividend from Tacere Stock

Dec 23, 2010
Premium

Benitec said this week that it has received a $161,674 dividend related to its stake in privately held RNAi drug shop Tacere Therapeutics.

In 2006, Benitec licensed its gene-silencing technology to Tacere for use in developing an expressed RNA-based treatment for hepatitis C (GSN 10/12/2006). The equity stake was part of the payment Benitec received for the license.

Filed under

Gene Silencing/Gene Editing
RNAi
expressed RNAi
Benitec
Tacere Therapeutics
Breaking News
The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.